DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Leuprorelin Associated With Radiotherapy Versus Leuprorelin Alone in T3 - T4 or pT3 (on Biopsy) N0, M0 Prostate Cancer

Information source: Takeda
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Prostatic Neoplasms, Locally Advanced

Intervention: Leuprorelin SR (Drug); Radiotherapy (Radiation); Flutamide (Drug)

Phase: Phase 3

Status: Completed

Sponsored by: Takeda

Official(s) and/or principal investigator(s):
Nicolas MOTTET, Dr, Principal Investigator, Affiliation: Clinique Mutualiste - Saint-Etienne
Pierre RICHAUD, Dr, Principal Investigator, Affiliation: Institut BERGONIÉ, Centre Régional de Lutte contre le Cancer, Bordeaux
Michel PENEAU, Dr, Principal Investigator, Affiliation: Martinique
Jean-Jacques MAZERON, Pr, Principal Investigator, Affiliation: Groupe Hospitalier PITIE-SALPETRIERE, Paris

Summary

The purpose of this study is to compare the efficacy and safety of combined radiotherapy and hormone therapy and hormone therapy alone in the treatment of clinically locally advanced prostate cancer (T3-T4 or pT3 on biopsy, N0, M0).

Clinical Details

Official title: Comparative Efficacy and Safety of Combined Radiotherapy and Adjuvant Hormone Therapy (Leuprorelin SR 11.25 mg) and Hormone Therapy Alone (Leuprorelin SR 11.25 mg) in Locally Advanced Prostate Cancer (T3-T4 or pT3 on Biopsy, N0, M0)

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Progression-free survival at 5 years

Secondary outcome:

Time to Biological Progression

Time to Clinical Progression

Overall Survival

Time to Locoregional Progression

Time to Onset of Metastatic Progression

Specific Survival

Number of Deaths linked to the disease

Detailed description: The drug being tested in this study is called leuprorelin SR. Leuprorelin SR is being tested to treat people who have prostate cancer. This study will look at the overall survival of people who take leuprorelin SR in addition to radiation therapy compared to those who take only leuprorelin SR. The study will enroll approximately 273 patients. Participants will be randomly assigned to one of the two treatment groups.

- Combined Radiotherapy and Hormone Therapy

- Hormone Therapy alone. All participants will receive leuprorelin injection every 3

months and flutamide tablets thrice daily for first 30 days as part of hormone therapy. Participants randomized to combined radiotherapy and hormone therapy group, will also receive radiotherapy 70 +/- 4 Gy in 35 fractions at a rate of 5 fractions of 2 Gy per week. This multi-center trial will be conducted in France and Tunisia. The overall time to participate in this study is 8 years. The scheduled duration of hormone therapy was 3 years in both arms, with an additional treatment-free follow-up period of 2 years i. e. a total follow-up period of 5 years. Post-protocol collection of information relative to survival will be performed after the end the 5-year follow-up period.

Eligibility

Minimum age: 18 Years. Maximum age: 80 Years. Gender(s): Male.

Criteria:

Inclusion Criteria:

- Histologically confirmed locally advanced adenocarcinoma of the prostate, graded: T3

or T4 or pT3 on biopsies (presence of tumour tissue in periprostatic fat observed on biopsies), N0 (absence of metastatic), M0 (no distant metastases detectable on the following examinations: bone scan, chest x-ray, abdominal and pelvic ultrasound).

- Patient in whom the prostatic adenocarcinoma has received no prior treatment of any

type, with the possible exception of transurethral resection due to obstructive symptoms.

- Patient with a Karnofsky index greater than or equal to (≥) 70.

- Patient aged under 80 years on the randomization date.

- Patient with a life expectancy of at least 7 years.

- Patient who, after having received clear information, gave his written consent

to participate and cooperate in the study.

- Patient for whom a recent blood test (less than [<] 2 months) has not

revealed elevated transaminases ≥ 3 times the normal laboratory range. Exclusion Criteria:

- Patient incapable of understanding the information supplied concerning the study or

of giving his consent, or having refused to sign the informed consent form,

- Patient for whom there is a risk that follow-up in compliance with the

conditions stipulated by the protocol will not be possible,

- Patient having already received prior treatment for prostate cancer,

excluding transurethral resection of the prostate to relieve obstruction,

- Patient having undergone surgical castration, or with a history of bilateral

adrenalectomy or hypophysectomy,

- Patient having had another cancer within the previous 5 years (including carcinoma in

situ of the bladder) excluding basocellular epithelioma or carcinoma in situ (other than in the bladder),

- Patient with lymph node or metastatic spread of the prostatic adenocarcinoma

suspected on imaging,

- Patient with a non-controlled severe active disease,

- Patient with a contraindication to external prostatic radiotherapy,

- Patient receiving or having received another experimental treatment within 3 months

prior to inclusion in the study,

- Patient with impaired liver function or elevated transaminases ≥3 times the normal

laboratory range.

Locations and Contacts

Clinique Mutualiste, Saint-etienne 42013, France
Additional Information

Starting date: March 2000
Last updated: July 27, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017